Teva Pharmaceutical Industries Limited (TEVA) Q1 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Hello and welcome to the Teva Pharmaceutical Industries Limited Q1 2026 earnings conference call. My name is Alex. I'll be coordinating today's call. If you'd like to ask a question at the end of the presentation, you may press star followed by one on your telephone keypad. And I hand it over to Chris Devo, SVP, Investor Relations. Please go ahead. Thank you, Alex. Good morning and good afternoon, everyone. Thank you for joining us on our first quarter call. I'd like to note that Before we posted our press release this morning on earnings, we also posted a press release on the MLX transaction, as well as a slide deck relating to that transaction. And you can find those materials in the same section as you can find our earnings materials. Before I turn the call over to our CEO, Richard Francis, I want to remind everyone that we will be making forward-looking statements on this call. The company cautions investors that any forward-looking statement involves risks and uncertainties and is not a guarantee of future performance. Actual results may differ materially from those expressed or implied in the forward-looking statements due to a variety of factors. These factors are described in earnings press release in our most recent 10Q and 10K filed with the SEC. Any statements we make are only as of today, and we undertake no obligation to update these statements subsequently. With that, Richard Francis. Thanks, Chris. Good morning and good afternoon, everybody. Thank you for joining the call. On the call with me today will be my colleague, Dr. Eric Hughes, head of R&D and chief medical officer, and Ellie Cleaf, the chief financial officer. So starting with, as I always do, on the pivot to growth strategy slide, we launched this pivot to growth strategy three years ago, an...